How Cannabis Fits Into Cancer Care: Symptom Management and Beyond
A clinical review found that cannabis may help cancer patients manage pain, nausea, appetite loss, insomnia, and depression, with emerging preclinical evidence suggesting possible direct anti-tumor effects.
Quick Facts
What This Study Found
This review examined the role of cannabis in cancer care across multiple domains. For symptom management, the evidence supported cannabis use for chemotherapy-induced nausea and vomiting, appetite stimulation, pain management (potentially synergistic with opioids), and peripheral neuropathy relief.
Inhaled cannabis was found to be more effective than placebo for peripheral neuropathy, and a pharmacokinetic study showed that vaporized cannabis did not significantly alter plasma opioid levels in patients on stable opioid therapy, suggesting safe co-administration with possible synergistic pain relief.
Beyond symptoms, the review noted a growing body of preclinical research showing anti-tumor effects of cannabinoids through mechanisms involving apoptosis, anti-angiogenesis, and metastasis inhibition. However, no clinical trials had been conducted to confirm these effects in humans.
Key Numbers
Vaporized cannabis did not produce clinically significant changes in plasma opioid levels. Multiple preclinical studies showed anti-tumor effects through apoptosis, anti-angiogenesis, and metastasis inhibition. No clinical trials on direct anti-cancer effects had been completed at the time of publication.
How They Did This
This was a clinical review article published in a medical oncology journal, synthesizing evidence from clinical trials, pharmacokinetic studies, preclinical research, and anecdotal reports about cannabis use in cancer care.
Why This Research Matters
Cancer patients often use cannabis, with or without medical guidance. This review provides oncologists and patients with an evidence-based framework for understanding where cannabis might fit into cancer care, from well-supported symptom management to speculative anti-tumor potential.
The Bigger Picture
The review highlights a gap between preclinical promise and clinical evidence for cannabis as a direct cancer treatment. While symptom management uses are better supported, the anti-tumor findings from laboratory and animal studies continue to drive interest in clinical trials.
What This Study Doesn't Tell Us
The review acknowledged a lack of clinical trials for direct anti-cancer effects. Anecdotal reports of remarkable responses do not constitute clinical evidence. The symptom management evidence, while more robust, still has gaps regarding optimal dosing, formulations, and patient selection.
Questions This Raises
- ?Will human clinical trials confirm the anti-tumor effects seen in preclinical research?
- ?What are the optimal dosing strategies for cannabis in cancer symptom management?
Trust & Context
- Key Stat:
- Vaporized cannabis did not alter plasma opioid levels, suggesting safe co-use with opioid pain medications
- Evidence Grade:
- This is a clinical review synthesizing evidence of varying quality. Symptom management evidence draws on clinical trials, while anti-tumor claims rest on preclinical data and anecdotal reports.
- Study Age:
- Published in 2016. Clinical trials on cannabis and cancer have continued since, though evidence for direct anti-tumor effects in humans remains limited.
- Original Title:
- Integrating cannabis into clinical cancer care.
- Published In:
- Current oncology (Toronto, Ont.), 23(2), S8-S14 (2016)
- Authors:
- Abrams, D I(2)
- Database ID:
- RTHC-01084
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis cure cancer?
There is no clinical trial evidence that cannabis cures cancer in humans. Preclinical studies (lab and animal models) have shown anti-tumor effects, but these findings have not been confirmed in human trials. The strongest evidence supports cannabis for managing cancer-related symptoms.
Is it safe to use cannabis alongside chemotherapy?
A pharmacokinetic study cited in this review found that vaporized cannabis did not significantly alter plasma levels of opioid medications. However, interactions with specific chemotherapy drugs have not been fully studied, and patients should discuss cannabis use with their oncology team.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01084APA
Abrams, D I. (2016). Integrating cannabis into clinical cancer care.. Current oncology (Toronto, Ont.), 23(2), S8-S14. https://doi.org/10.3747/co.23.3099
MLA
Abrams, D I. "Integrating cannabis into clinical cancer care.." Current oncology (Toronto, 2016. https://doi.org/10.3747/co.23.3099
RethinkTHC
RethinkTHC Research Database. "Integrating cannabis into clinical cancer care." RTHC-01084. Retrieved from https://rethinkthc.com/research/abrams-2016-integrating-cannabis-into-clinical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.